Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Flinn, Ian W., O’Brien, Susan, Kahl, Brad, Patel, Manish, Oki, Yasuhiro, Foss, Francine F., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan A., Jain, Nitin, Kelly, Virginia M., Allen, Kerstin, Douglas, Mark, Sweeney, Jennifer, Kelly, Patrick, Horwitz, Steven
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033052/
https://ncbi.nlm.nih.gov/pubmed/29191916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-786566
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky